It’s been a while but here’s some new stuff (dare I say n3#s in Australia)
Don’t get too excited, it’s not guidelines developed in consultation with the lived experience of diabetes, it’s health professional developed continuously contemporary guidelines. Most clinical guidelines are out of date before they are disseminated, by the time everybody involved has commented, revised, argued about, watered down, etc etc a guideline the technology and treatment paradigms have changed. In an attempt to overcome this, a thing called “living guidelines have been developed”.
The diabetes living guidelines are a collaboration between the Australian Diabetes Society (ADS), Diabetes Australia (DA), the Australian Diabetes Educators Association and the Australasian Paediatric Endocrine Group (APEG), with representation from The Royal Australian College of General Practitioners (RACGP), the Australian Department of Health and Cochrane Australia. I do wonder how much input people with diabetes have had.
The living guideline for type 1 diabetes is “Medical Device Technology for the Management of Type 1 Diabetes”
In many ways the guidelines seem to state the obvious that we’ve been saying within the community of people with type 1, there are lots of benefits to pumps and CGM but there are downsides and expense, so it should be your choice. I guess these guidelines are more for those out of date practitioners who would prevent their patients accessing technology, if you’re stuck with one or more of these, then the guidelines can assist in pressing your case.
The guidelines are very readable and can be accessed here.
The Australian Health Department’s Covid vaccine eligibility checker indicates that people with diabetes will be in stage 1B of the vaccine roll out, expected to start in mid-March. The Health Department website has a lot of information about preparing for the vaccine and the roll outs.
Price Hike for CGM
I understand the cost of dex sensors has jumped markedly in Australia, what’s been your experience. Yet again it seems a disappointing outcome from pharma, surely more realistic pricing would increase useage and achieve economies of scale.